J. Reel

发表

SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF BENZOPHENONES AS INHIBITORS OF CATHEPSIN D

D. R. Berry, S. Little, C. Whitesitt, 1996 .

Endocrine Screening Methods Workshop report: detection of estrogenic and androgenic hormonal and antihormonal activity for chemicals that act via receptor or steroidogenic enzyme mechanisms.

R. Tyl, J. Giesy, T. Zacharewski, 1997, Reproductive toxicology.

Reconstitution of synaptic Ion channels from rodent and human brain in Xenopus oocytes: a biochemical and electrophysiological characterization

E. Sher, J. Reel, K. Gardinier, 2016, Journal of neurochemistry.

A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.

D. Nelson, H. Bryant, M. Baez, 1996, Life sciences.

Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.

R. Campbell, P. Iversen, M. Clay, 2004, Journal of medicinal chemistry.

The development of potent and selective bisarylmaleimide GSK3 inhibitors.

R. Campbell, B. Anderson, T. Engler, 2005, Bioorganic & medicinal chemistry letters.

Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists.

C. Whitesitt, R. Simon, J. Reel, 1994, Journal of medicinal chemistry.

Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.

D. Zimmerman, J. Reel, J. Leander, 1987, The Journal of pharmacology and experimental therapeutics.

Chiral recognition of the angiotensin II (AT1) receptor by a highly potent phenoxyproline octanoamide

C. J. Barnett, D. B. Boyd, J. Deeter, 1994 .

3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.

D. Wong, C. Mitch, A. Takemori, 1993, Journal of medicinal chemistry.

Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism

J. Isaac, D. Bredt, E. Nisenbaum, 2016, Nature Medicine.

Modulation of TARP γ8–Containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain

D. Bredt, E. Nisenbaum, Y. Qian, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors

S. Mitchell, G. Gilmour, J. Witkin, 2017, Neuropharmacology.

Targeted Blockade of TARP-γ8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611).

Jodi L. Smith, J. Witkin, D. Gehlert, 2017, CNS & neurological disorders drug targets.

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.

D. Bredt, G. Stephenson, P. Ornstein, 2016, Journal of medicinal chemistry.

Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.

P. Hipskind, Hong Gao, J. Manro, 2013 .

Non-peptide angiotensin II receptor antagonists discriminate subtypes of 125I-angiotensin II binding sites in the rat brain.

D. Gehlert, J. Reel, S. Gackenheimer, 1990, European journal of pharmacology.

Discovery of the First α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) γ-8.

D. Bredt, P. Ornstein, J. Witkin, 2016, Journal of medicinal chemistry.